SAREPTA THERAPEUTICS INC

SRPTNASDAQ

🏆 #1999 by market capEarnings Nov 2 · PostUS Equity

$18.65▼ $0.15 (−0.82%)

Market closed · at close

🔔

Track SRPT

Get earnings, price moves & breaking news on Telegram

Track

24h▼ 0.8%

7d▼ 1.5%

14d▼ 5.6%

30d▼ 11.3%

ytd▼ 13.3%

1y▼ 3.2%

🏦Market Cap

$1.97B

Small Cap

📈Revenue Growth (YoY)

+15.6%

Healthy

📊Gross Margin

58.6%

Healthy

💵FCF Margin

-6.7%

Thin

⚖️P/S Ratio

1.0x

Cheap

Otter Score

Fair

Trading Snapshot

Day Range: $18.57 – $19.01
52-Week Range: $14.68 – $25.32
Volume: $3.96B
Avg Volume: $4.72B
Shares Outstanding: 105.6M
Next Earnings: Dec 15, 2026

Fundamentals Snapshot

Annual Revenue: $2.20B
Last Q Revenue: $401M
P/E Ratio: -13.1
P/S Ratio: 1.0x
EPS (TTM): $-1.30
Dividend Yield: 0.00%
Dilution (1yr): −3.4%

Why Investors Own SRPT

✓High-growth profile — revenue up -1.9% YoY with expanding US Equity exposure.
✓Healthy economics — 74% gross margin and 20% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

SAREPTA THERAPEUTICS INC

SRPT

Financial Trends

Revenue

$2.2B▲ +15.6% YoY

Gross Margin

59.9%▼ −28.0% YoY

Operating Income

−$658M▼ −401.6% YoY

Free Cash Flow

−$307M▼ −12.8% YoY

Shares Outstanding

104.8M▼ −3.4% YoY

Net Cash

−$238M▲ +$2M YoY

StockOtter · stockotter.space

About SAREPTA THERAPEUTICS INC

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company dedicated to the discovery and advancement of genetic treatment modalities, including RNA-targeted therapeutics and gene therapies, specifically for rare diseases. The company currently offers two approved treatments: EXONDYS 51, prescribed for Duchenne muscular dystrophy (DMD) patients with confirmed dystrophin gene mutations amenable to exon 51 skipping, and VYONDYS 53, for DMD patients with exon 53 skipping mutations. Sarepta's development pipeline includes AMONDYS 45, an exon-skipping product candidate utilizing phosphorodiamidate morpholino oligomer chemistry for exon 45; SRP-5051, a peptide-conjugated PMO designed to target exon 51 of dystrophin pre-mRNA; and gene therapy programs such as SRP-9001 for DMD and SRP-9003 for limb-girdle muscular dystrophies. The company maintains collaborative agreements with organizations like F. Hoffman-La Roche Ltd, Nationwide Children's Hospital, Lysogene, Duke University, Genethon, and StrideBio. Founded in 1980, Sarepta Therapeutics is headquartered in Cambridge, Massachusetts.

🦦